| abstract |
HLA-matched activated lymphocytes are used to achieve engraftment stability after hematopoietic stem cell transplantation.n n n After proliferation and activation of HLA-matched lymphocytes in monocyte cells isolated from peripheral blood or umbilical cord blood, the isolates are also collected and used as a engraftment stable composition after hematopoietic stem cell transplantation mainly containing HLA-matched lymphocytes. As a result, it can be widely used for preventing engraftment failure and engraftment treatment after hematopoietic stem cell transplantation. In addition, although the dosage of the composition of the present invention varies depending on the age, symptoms, and the like of the patient, 0.2 to 20 mg / kg / day of the humanized antibody is administered to a mammal including a human.n n n Administration is carried out by intravenous injection once a day (single administration or daily administration) or intermittently 1 to 3 times per week, once every 2 to 3 weeks. |